z-logo
Premium
Treatment intensification with an insulin degludec ( IDeg )/insulin aspart ( IAsp ) co‐formulation twice daily compared with basal IDeg and prandial IAsp in type 2 diabetes: a randomized, controlled phase III trial
Author(s) -
Rodbard H. W.,
Cariou B.,
Pieber T. R.,
Endahl L. A.,
Zacho J.,
Cooper J. G.
Publication year - 2016
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/dom.12609
Subject(s) - insulin degludec , medicine , endocrinology , insulin aspart , type 2 diabetes , insulin , basal (medicine) , diabetes mellitus , basal insulin
Aims To evaluate the efficacy and safety of two insulin intensification strategies for patients with type 2 diabetes previously treated with basal insulin – insulin degludec ( IDeg ) and insulin aspart ( IAsp ) – administered as a co‐formulation ( IDegAsp ) or as a basal‐bolus regimen ( IDeg and IAsp in separate injections). Methods This 26‐week, open‐label, treat‐to‐target, phase IIIb , non‐inferiority trial randomized patients (1 : 1) to IDegAsp twice daily with main meals (n = 138; IDegAsp group) or IDeg once daily and IAsp 2–4 times daily (n = 136; IDeg + IAsp group). Results After 26 weeks, the mean glycated haemoglobin ( HbA1c ) level was 7.0% (53 mmol/mol) for the IDegAsp group and 6.8% (51 mmol/mol) for the IDeg + IAsp group (Δ% HbA1c from baseline −1.31 and −1.50%, respectively). The non‐inferiority of IDegAsp versus IDeg + IAsp was not confirmed for mean change in HbA1c [estimated treatment difference ( ETD ) 0.18, 95% confidence interval ( CI ) −0.04, 0.41; p = non‐significant]. No significant differences were observed in the proportion of patients achieving HbA1c <7.0% (56.5 and 59.6%, respectively). IDegAsp treatment resulted in a significantly lower total daily insulin dose, a smaller change in body weight, numerically lower rates of confirmed hypoglycaemia (self‐reported plasma glucose <3.1 mmol/l; rate ratio 0.81; p = non‐significant), and nocturnal confirmed hypoglycaemic episodes (rate ratio 0.80; p = non‐significant) versus IDeg + IAsp . Patient‐reported outcome scores for social functioning were significantly higher for IDegAsp versus IDeg + IAsp ( ETD 2.2; 95% CI 0.3, 4.1; p < 0.05). Conclusions Both intensification strategies effectively improved glycaemic control. Although non‐inferiority was not confirmed, there were no significant differences between the groups that could affect clinical utility.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here